

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**丽珠医药**  
**LIVZON**

**麗珠醫藥集團股份有限公司**

**LIVZON PHARMACEUTICAL GROUP INC.\***

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1513)**

## **Date of Board Meeting**

The board of directors (the “**Board**”) of Livzon Pharmaceutical Group Inc.\* 麗珠醫藥集團股份有限公司 (the “**Company**”) hereby announces that a meeting of the Board of the Company will be held on Thursday, 28 March 2024 for the purpose of considering and approving the annual results of the Company and its subsidiaries for the year ended 31 December 2023, considering the recommendation of a final dividend (if applicable) and transacting any other business (if any).

By order of the Board  
**Livzon Pharmaceutical Group Inc.\***  
麗珠醫藥集團股份有限公司  
**Yang Liang**  
*Company Secretary*

Zhuhai, China  
28 February 2024

*As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.*

*\* For identification purpose only*